Keyword(s)
Rapastinel, GLYX-13, GLYX 13, UNII-6A1X56B95E, GLYX-13 trifluoroacetate, TPPT-amide trifluoroacetate, 117928-94-6, TPPT-amide, GLYX-13 peptide, L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate; Thr-Pro-Pro-Thr-NH2 trifluoroacetate
IUPAC
(2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide
Comments
nevitdilmen
Tue, 2016-09-13 12:09
Permalink
Short info
Rapastinel (INN) (former developmental code names GLYX-13, BV-102) is a novel antidepressant that is under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder.